Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced CBS reduction route for Tasimelteon intermediate. Enhances purity and supply chain reliability for global pharmaceutical manufacturing partners.
Novel patent CN105622464A enables safer chiral hydrazine production with improved purity and supply chain reliability for global pharmaceutical manufacturers.
Patent CN105884781B details a chiral catalytic route for Tofacitinib Citrate, offering high purity and cost reduction in pharmaceutical intermediates manufacturing for global supply chains.
Novel chiral catalytic route for Tofacitinib Citrate. Enhances purity, reduces cost, ensures supply chain reliability for pharmaceutical manufacturing.
Patent CN110129382B details a green enzymatic route for high-purity chiral alcohols, offering significant supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN106701698B reveals high-efficiency SsCR enzyme for chiral alcohol synthesis. Achieves 99.9% ee and 500mmol/L substrate concentration for scalable manufacturing.
Patent CN110627673B details a high-purity route for Formoterol intermediates using borane reduction, offering significant cost and supply chain advantages for API manufacturers.
Patent CN115594600A reveals a safer, one-step synthesis of chiral (R)-3-aminobutanol using borohydride, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN114014787B details a high-purity asymmetric route for florfenicol intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN101066924B reveals a streamlined chemical synthesis for Orlistat intermediates, offering high purity and scalable production for pharmaceutical manufacturers.
Patent CN101824438A reveals microbial conversion for high-purity chiral intermediates. Offers cost reduction and scalable supply chain solutions for pharmaceutical manufacturing partners globally.
Patent CN1124962A details novel chiral catalysts for high-ee alcohol production, offering scalable routes for API intermediates and cost-effective manufacturing solutions.
Patent CN104592110A reveals cost-effective chiral reduction for Montelukast intermediate ensuring high purity and scalable supply chain reliability for global pharmaceutical manufacturers
Patent CN1259122A details a novel asymmetric Birch reduction for chiral 3,4-dehydroprolines, offering superior yields and eliminating toxic reagents for cost-effective API manufacturing.
Patent CN113512569B details a green enzymatic route for Lopinavir intermediates. Achieve high purity and cost reduction in API manufacturing with our advanced biocatalytic solutions.
Patent CN101319236A details a green biocatalytic method for chiral alcohols using ionic liquids. Achieve high purity and cost reduction in pharma intermediate manufacturing with scalable processes.
Novel biocatalytic route for chiral alcohol intermediates ensures >99% ee and scalable production for beta-3 agonists.
Patent CN105473546A details a safer synthesis route for R-biphenylalaninol. This method offers cost reduction in API intermediate manufacturing and supply chain reliability.
Patent CN103502208B reveals mild diamine synthesis avoiding Birch reduction. Enables cost reduction in pharmaceutical intermediate manufacturing and supply chain reliability.
Novel synthesis of Vilanterol intermediate CN105646285A offers higher yield and cost efficiency. Reliable pharmaceutical intermediates supplier for global supply chains.